As 2014 winds down, and Gilead Sciences keeps winding up hep C sales by the billion, AbbVie waits, vibrating with anticipation. Its three-drug cocktail is up for FDA approval any day now, and the Illinois-based company is ready to challenge Gilead for market share.
The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail strategy.
AbbVie is one step closer to challenging Gilead Sciences' dominance in the hepatitis C market, securing a likely European approval for its rival combo treatment as it awaits a U.S. nod.
Open up the floodgates: Gilead's hep C wonder-cocktail, Harvoni, has won approval in Europe.
AbbVie is heralding positive new data on its hepatitis C cocktail, touting the treatment's benefit in some tough-to-treat patients as it prepares for a head-to-head competition with market leader Gilead Sciences.
After sending out signals that it might be running into trouble with a short-duration study of a new triple combination drug for its hepatitis C regimen, Merck investigators hailed the clear success of an 8-week test but confirmed analysts' fears in a batch of 4-week data released at the meeting of the American Association for the Study of Liver Diseases.
Bristol-Myers Squibb is taking Gilead's lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing agreements with generics makers. But according to some critics, that's not enough.
Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.
Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.